

13. A compound according to claim 1 which is 3-(3-(3,5-Dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
14. A compound according to claim 1 which is (*S*)-3-(3-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
15. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in therapy.
16. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition for which an $\alpha_v\beta_6$ receptor antagonist is indicated.
17. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of idiopathic pulmonary fibrosis.
18. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of disorders in which antagonism of an $\alpha_v\beta_6$ receptor is beneficial in a human ~~comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~
19. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of disorders in which antagonism of an $\alpha_v\beta_6$ receptor is beneficial in a human ~~comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~
20. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of fibrotic diseases in a human ~~comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~
21. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of fibrotic diseases in a human ~~comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~
22. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a

medicament for the treatment of idiopathic pulmonary fibrosis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

23. ~~A method~~ Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of idiopathic pulmonary fibrosis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.